Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
$20.84
$0.28(1.32%)
At close: 4:00 PM EST
$20.84
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$10.57 - $24.35
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.32M
Market Cap
$3.32B
Enterprise Value$3.32B
Total Cash (Recent Filing)$848.20M
Total Debt (Recent Filing)$44.40M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Mar 02, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding156,158,370
10 Day Avg. Volume1,584,851
30 Day Avg. Volume1,323,608
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.73
Price to Sales (P/S)0.00
P/FCF Ratio-9.22
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.22
Forecast
1Y Price Target
$32.36Price Target Upside55.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy DataPublished clinical results showing large and sustained reductions in disease biomarkers and neurodegeneration markers suggest tividenofusp may offer meaningful clinical differentiation compared with existing treatments.
Financing And Cash RunwayRoyalty Pharma financing together with a strong cash position supports commercialization planning and reduces near-term capital risk for launch execution.
Regulatory ApprovalPotential FDA approval of tividenofusp could establish the first transferrin receptor–shuttled therapy, creating a new therapeutic class with limited direct competition.
Bears Say
Commercial Adoption And Treatment LogisticsSwitching patients to tividenofusp requires a multi-month hospital-based treatment period during transition, which could hinder uptake among patients who currently receive therapy at home.
Preclinical Safety RiskFDA-requested IND amendments for DNL952 after preclinical hypersensitivity findings raise safety uncertainties that may complicate dose selection and slow development progress.
Regulatory SetbacksLoss of an anticipated priority review voucher and a clinical hold on Pompe programs constitute regulatory setbacks that could delay projected commercialization and add uncertainty.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $10.57 and its highest was $24.34 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.32B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 31 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.748 by $0.008.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.74.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 156,158,370 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.748. Following the earnings report the stock price went up 4.233%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.36 (55.28% Upside)
$32.36 (55.28% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 114.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $864.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.31%
12-Months-Change
Fundamentals
Return on Equity
-44.44%
Trailing 12-Months
Asset Growth
-27.40%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
DNLI Stock 12 Month Forecast
Average Price Target
$32.36
▲(55.28% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
6.75% Insiders
24.65% Mutual Funds
0.26% Other Institutional Investors
53.01% Public Companies and
Individual Investors